Medtronic Appoints Chad Spooner as CFO Ahead of MiniMed's Spin-off

Medtronic’s Strategic Move towards Independence

In a significant move to bolster its newly distinct identity, Medtronic plc, a global frontrunner in health technology, has announced the appointment of Chad Spooner as the Chief Financial Officer (CFO) of its upcoming MiniMed entity, effective July 14, 2025. This appointment comes as Medtronic gears up for its planned separation of MiniMed into a fully independent public company, marking a potentially transformative chapter for the diabetes care leader.

Chad Spooner arrives at MiniMed armed with over 25 years of profound financial expertise, having accumulated leadership experience across various sectors including healthcare, consumer goods, and industrial fields. Most recently, he served as CFO of BIC, renowned for its innovative consumer products, where his financial stewardship played a pivotal role in steering the company towards sustainable growth and operational efficiency. Before joining BIC, he took on significant roles at General Electric, where he honed his finance capabilities through various management positions in corporate audit and financial planning.

Speaking about Spooner's appointment, Que Dallara, Executive Vice President and President of Medtronic Diabetes, expressed confidence in Spooner’s ability to drive transformation and growth. "Chad’s deep financial expertise and proven leadership will be instrumental as we prepare for our next chapter as an independent company,” stated Dallara, highlighting the ongoing commitment to enhancing diabetes care.

The new MiniMed entity aims to honor its rich 40-year legacy of advancing diabetes treatment, with a mission centered on making diabetes management more predictable and accessible. This transition reflects Medtronic’s strategic vision to focus on innovation, particularly important as diabetes care continues evolving with new technologies.

Under Spooner’s financial leadership, MiniMed seeks to not only accelerate growth but also deliver enhanced shareholder value. This objective aligns with Medtronic's broader goal: to leverage advancements in diabetic technology, including next-generation continuous glucose monitors (CGM) and intelligent insulin delivery systems. By enhancing operational initiatives, MiniMed aims to further its mission of empowering individuals managing diabetes, thus allowing them to embrace life with greater confidence.

In anticipation of the separation, Medtronic has laid out a detailed plan set to unfold over the next 18 months. This period will involve multiple capital market transactions and regulatory steps to ensure a smooth transition, subject to necessary approvals and consultations. With an eye on compliance and strategic positioning, the company is determined to navigate this transition effectively while also addressing the healthcare landscape's evolving demands.

As MiniMed prepares to stand on its own, the emphasis on innovation, quality care, and financial robustness will likely position it favorably in the competitive diabetes care market. Chad Spooner, alongside the MiniMed leadership team, is poised to shape the future of the newly independent organization and to drive impactful changes that resonate with those living with diabetes worldwide.

Conclusion

In conclusion, the appointment of Chad Spooner signals more than just a leadership change; it represents Medtronic’s commitment to fostering an agile, innovative MiniMed. With a dedicated focus on enhancing diabetes management tools and a clear roadmap ahead, the future seems promising for both the brand and the communities it serves. This strategic move sets the foundation for long-term success and reaffirms the mission of making diabetes management seamless and predictable, enabling individuals to lead full lives.